Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Nanoparticulate drug delivery systems [[electronic resource] ] : strategies, technologies, and applications / / edited by Yoon Yeo
| Nanoparticulate drug delivery systems [[electronic resource] ] : strategies, technologies, and applications / / edited by Yoon Yeo |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) | YeoYoon |
| Soggetto topico |
Nanoparticles
Drug delivery systems Pharmaceutical biotechnology |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-299-24223-5
1-118-57054-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications; Contents; Preface; Contributors; 1 Tumor-Targeted Nanoparticles: State-of-the-Art and Remaining Challenges; 1.1 INTRODUCTION; 1.2 FUNCTIONS OF NANOPARTICLES; 1.3 TUMOR-TARGETED NANOPARTICLES; 1.3.1 Passive Targeting; 1.3.2 Active Targeting; 1.3.3 Target-Activated Systems; 1.4 REMAINING CHALLENGES IN THE DEVELOPMENT OF TUMOR-TARGETED NANOPARTICLES; 1.4.1 NP Stability; 1.4.2 Heterogeneous Tumor Vasculature; 1.4.3 NP Distribution in Tumors; 1.4.4 Regulatory Considerations; 1.5 FUTURE PERSPECTIVES
1.5.1 In Vitro Models1.5.2 In Vivo Models; 1.5.3 New Targets; 1.5.4 New Therapeutic Agents; Acknowledgments; REFERENCES; 2 Applications of Ligand-Engineered Nanomedicines; 2.1 INTRODUCTION; 2.1.1 Nanoparticulate Drug Delivery; 2.1.2 Engineered Nanoparticulate Drug Delivery; 2.2 LIGAND-MEDIATED DELIVERY; 2.2.1 Antibodies; 2.2.2 Peptides and Proteins; 2.2.3 Sugars and Polysaccharides; 2.2.4 Small Molecule Chemicals; 2.3 CURRENT CHALLENGES IN CLINICAL DEVELOPMENT OF LIGAND-MODIFIED NANOMEDICINE; 2.3.1 Nonclinical and Clinical Studies; 2.3.2 Challenges and Future Perspectives; 2.4 CONCLUSIONS AcknowledgmentsREFERENCES; 3 Lipid Nanoparticles for the Delivery of Nucleic Acids; 3.1 INTRODUCTION; 3.2 BARRIERS TO SYSTEMIC GENE DELIVERY; 3.2.1 Extracellular Barriers; 3.2.2 Intracellular Barriers; 3.3 COMPONENTS OF LNPs; 3.3.1 Cationic Lipid; 3.3.2 Neutral Lipid; 3.3.3 Anionic Lipid; 3.3.4 PEG-Lipid Conjugates; 3.4 FORMULATIONS OF THE LNP FOR NUCLEIC ACIDS ENCAPSULATION; 3.4.1 Self-Assembly; 3.4.2 Detergent Dialysis; 3.4.3 Nanometric Calcium Phosphate/siRNA Precipitation; 3.5 ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS WITH LNPs; 3.5.1 Brain-Targeted Delivery; 3.5.2 Liver-Targeted Delivery 3.5.3 Lung-Targeted Delivery3.5.4 Kidney-Targeted Delivery; 3.6 CURRENT CHALLENGES TO THE DEVELOPMENT OF LNPs; 3.7 FUTURE PERSPECTIVES; Acknowledgments; REFERENCES; 4 Photosensitive Liposomes as Potential Targeted Therapeutic Agents; 4.1 INTRODUCTION; 4.2 EXPERIMENTAL PROCEDURES; 4.2.1 Materials; 4.2.2 Synthesis of 1-Bromo-3-hexadecylthiobenzene (1); 4.2.3 Synthesis of 9-[3-Hexadecylthiophenyl] anthracene (2); 4.2.4 Synthesis of 9-[3-Hexadecyl-3'-cyanobenzylsulfonium] phenylanthracene Trifluoromethanesulfonate (C16-An-PAG) (3); 4.2.5 Liposome Preparation; 4.2.6 Dynamic Light Scattering 4.2.7 Photoexcitation Method4.2.8 Calcium Ion Release Assay; 4.2.9 Negative Stain Transmission Electron Microscopy; 4.2.10 Animal Studies; 4.3 RESULTS AND DISCUSSION; 4.3.1 DOPE:LysoPlsC Liposomes Using C16-An-PAG as a Photosensitizer; 4.3.2 PPlsC Liposomes Using Bchl a as a Photosensitizer; 4.3.3 Folate Receptor (FR)-Targeted DPPlsC Liposomes Using AlPcS4-4 as a Photosensitizer; 4.4 CONCLUSIONS; 4.5 PROSPECTS FOR LIGHT-ACTIVATED LIPOSOMAL DRUG DELIVERY; Acknowledgments; REFERENCES; 5 Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery 5.1 RECENT ADVANCES IN DENDRITIC NANOMATERIALS |
| Record Nr. | UNINA-9910465388103321 |
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanoparticulate drug delivery systems [[electronic resource] ] : strategies, technologies, and applications / / edited by Yoon Yeo
| Nanoparticulate drug delivery systems [[electronic resource] ] : strategies, technologies, and applications / / edited by Yoon Yeo |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) | YeoYoon |
| Soggetto topico |
Nanoparticles
Drug delivery systems Pharmaceutical biotechnology |
| ISBN |
1-299-24223-5
1-118-57054-5 |
| Classificazione | SCI013060 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications; Contents; Preface; Contributors; 1 Tumor-Targeted Nanoparticles: State-of-the-Art and Remaining Challenges; 1.1 INTRODUCTION; 1.2 FUNCTIONS OF NANOPARTICLES; 1.3 TUMOR-TARGETED NANOPARTICLES; 1.3.1 Passive Targeting; 1.3.2 Active Targeting; 1.3.3 Target-Activated Systems; 1.4 REMAINING CHALLENGES IN THE DEVELOPMENT OF TUMOR-TARGETED NANOPARTICLES; 1.4.1 NP Stability; 1.4.2 Heterogeneous Tumor Vasculature; 1.4.3 NP Distribution in Tumors; 1.4.4 Regulatory Considerations; 1.5 FUTURE PERSPECTIVES
1.5.1 In Vitro Models1.5.2 In Vivo Models; 1.5.3 New Targets; 1.5.4 New Therapeutic Agents; Acknowledgments; REFERENCES; 2 Applications of Ligand-Engineered Nanomedicines; 2.1 INTRODUCTION; 2.1.1 Nanoparticulate Drug Delivery; 2.1.2 Engineered Nanoparticulate Drug Delivery; 2.2 LIGAND-MEDIATED DELIVERY; 2.2.1 Antibodies; 2.2.2 Peptides and Proteins; 2.2.3 Sugars and Polysaccharides; 2.2.4 Small Molecule Chemicals; 2.3 CURRENT CHALLENGES IN CLINICAL DEVELOPMENT OF LIGAND-MODIFIED NANOMEDICINE; 2.3.1 Nonclinical and Clinical Studies; 2.3.2 Challenges and Future Perspectives; 2.4 CONCLUSIONS AcknowledgmentsREFERENCES; 3 Lipid Nanoparticles for the Delivery of Nucleic Acids; 3.1 INTRODUCTION; 3.2 BARRIERS TO SYSTEMIC GENE DELIVERY; 3.2.1 Extracellular Barriers; 3.2.2 Intracellular Barriers; 3.3 COMPONENTS OF LNPs; 3.3.1 Cationic Lipid; 3.3.2 Neutral Lipid; 3.3.3 Anionic Lipid; 3.3.4 PEG-Lipid Conjugates; 3.4 FORMULATIONS OF THE LNP FOR NUCLEIC ACIDS ENCAPSULATION; 3.4.1 Self-Assembly; 3.4.2 Detergent Dialysis; 3.4.3 Nanometric Calcium Phosphate/siRNA Precipitation; 3.5 ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS WITH LNPs; 3.5.1 Brain-Targeted Delivery; 3.5.2 Liver-Targeted Delivery 3.5.3 Lung-Targeted Delivery3.5.4 Kidney-Targeted Delivery; 3.6 CURRENT CHALLENGES TO THE DEVELOPMENT OF LNPs; 3.7 FUTURE PERSPECTIVES; Acknowledgments; REFERENCES; 4 Photosensitive Liposomes as Potential Targeted Therapeutic Agents; 4.1 INTRODUCTION; 4.2 EXPERIMENTAL PROCEDURES; 4.2.1 Materials; 4.2.2 Synthesis of 1-Bromo-3-hexadecylthiobenzene (1); 4.2.3 Synthesis of 9-[3-Hexadecylthiophenyl] anthracene (2); 4.2.4 Synthesis of 9-[3-Hexadecyl-3'-cyanobenzylsulfonium] phenylanthracene Trifluoromethanesulfonate (C16-An-PAG) (3); 4.2.5 Liposome Preparation; 4.2.6 Dynamic Light Scattering 4.2.7 Photoexcitation Method4.2.8 Calcium Ion Release Assay; 4.2.9 Negative Stain Transmission Electron Microscopy; 4.2.10 Animal Studies; 4.3 RESULTS AND DISCUSSION; 4.3.1 DOPE:LysoPlsC Liposomes Using C16-An-PAG as a Photosensitizer; 4.3.2 PPlsC Liposomes Using Bchl a as a Photosensitizer; 4.3.3 Folate Receptor (FR)-Targeted DPPlsC Liposomes Using AlPcS4-4 as a Photosensitizer; 4.4 CONCLUSIONS; 4.5 PROSPECTS FOR LIGHT-ACTIVATED LIPOSOMAL DRUG DELIVERY; Acknowledgments; REFERENCES; 5 Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery 5.1 RECENT ADVANCES IN DENDRITIC NANOMATERIALS |
| Record Nr. | UNINA-9910792080103321 |
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanoparticulate drug delivery systems : strategies, technologies, and applications / / edited by Yoon Yeo
| Nanoparticulate drug delivery systems : strategies, technologies, and applications / / edited by Yoon Yeo |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) | YeoYoon |
| Soggetto topico |
Nanoparticles
Drug delivery systems Pharmaceutical biotechnology |
| ISBN |
1-299-24223-5
1-118-57054-5 |
| Classificazione | SCI013060 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications; Contents; Preface; Contributors; 1 Tumor-Targeted Nanoparticles: State-of-the-Art and Remaining Challenges; 1.1 INTRODUCTION; 1.2 FUNCTIONS OF NANOPARTICLES; 1.3 TUMOR-TARGETED NANOPARTICLES; 1.3.1 Passive Targeting; 1.3.2 Active Targeting; 1.3.3 Target-Activated Systems; 1.4 REMAINING CHALLENGES IN THE DEVELOPMENT OF TUMOR-TARGETED NANOPARTICLES; 1.4.1 NP Stability; 1.4.2 Heterogeneous Tumor Vasculature; 1.4.3 NP Distribution in Tumors; 1.4.4 Regulatory Considerations; 1.5 FUTURE PERSPECTIVES
1.5.1 In Vitro Models1.5.2 In Vivo Models; 1.5.3 New Targets; 1.5.4 New Therapeutic Agents; Acknowledgments; REFERENCES; 2 Applications of Ligand-Engineered Nanomedicines; 2.1 INTRODUCTION; 2.1.1 Nanoparticulate Drug Delivery; 2.1.2 Engineered Nanoparticulate Drug Delivery; 2.2 LIGAND-MEDIATED DELIVERY; 2.2.1 Antibodies; 2.2.2 Peptides and Proteins; 2.2.3 Sugars and Polysaccharides; 2.2.4 Small Molecule Chemicals; 2.3 CURRENT CHALLENGES IN CLINICAL DEVELOPMENT OF LIGAND-MODIFIED NANOMEDICINE; 2.3.1 Nonclinical and Clinical Studies; 2.3.2 Challenges and Future Perspectives; 2.4 CONCLUSIONS AcknowledgmentsREFERENCES; 3 Lipid Nanoparticles for the Delivery of Nucleic Acids; 3.1 INTRODUCTION; 3.2 BARRIERS TO SYSTEMIC GENE DELIVERY; 3.2.1 Extracellular Barriers; 3.2.2 Intracellular Barriers; 3.3 COMPONENTS OF LNPs; 3.3.1 Cationic Lipid; 3.3.2 Neutral Lipid; 3.3.3 Anionic Lipid; 3.3.4 PEG-Lipid Conjugates; 3.4 FORMULATIONS OF THE LNP FOR NUCLEIC ACIDS ENCAPSULATION; 3.4.1 Self-Assembly; 3.4.2 Detergent Dialysis; 3.4.3 Nanometric Calcium Phosphate/siRNA Precipitation; 3.5 ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS WITH LNPs; 3.5.1 Brain-Targeted Delivery; 3.5.2 Liver-Targeted Delivery 3.5.3 Lung-Targeted Delivery3.5.4 Kidney-Targeted Delivery; 3.6 CURRENT CHALLENGES TO THE DEVELOPMENT OF LNPs; 3.7 FUTURE PERSPECTIVES; Acknowledgments; REFERENCES; 4 Photosensitive Liposomes as Potential Targeted Therapeutic Agents; 4.1 INTRODUCTION; 4.2 EXPERIMENTAL PROCEDURES; 4.2.1 Materials; 4.2.2 Synthesis of 1-Bromo-3-hexadecylthiobenzene (1); 4.2.3 Synthesis of 9-[3-Hexadecylthiophenyl] anthracene (2); 4.2.4 Synthesis of 9-[3-Hexadecyl-3'-cyanobenzylsulfonium] phenylanthracene Trifluoromethanesulfonate (C16-An-PAG) (3); 4.2.5 Liposome Preparation; 4.2.6 Dynamic Light Scattering 4.2.7 Photoexcitation Method4.2.8 Calcium Ion Release Assay; 4.2.9 Negative Stain Transmission Electron Microscopy; 4.2.10 Animal Studies; 4.3 RESULTS AND DISCUSSION; 4.3.1 DOPE:LysoPlsC Liposomes Using C16-An-PAG as a Photosensitizer; 4.3.2 PPlsC Liposomes Using Bchl a as a Photosensitizer; 4.3.3 Folate Receptor (FR)-Targeted DPPlsC Liposomes Using AlPcS4-4 as a Photosensitizer; 4.4 CONCLUSIONS; 4.5 PROSPECTS FOR LIGHT-ACTIVATED LIPOSOMAL DRUG DELIVERY; Acknowledgments; REFERENCES; 5 Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery 5.1 RECENT ADVANCES IN DENDRITIC NANOMATERIALS |
| Record Nr. | UNINA-9911091096703321 |
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanoparticulate drug delivery systems : strategies, technologies, and applications / / edited by Yoon Yeo
| Nanoparticulate drug delivery systems : strategies, technologies, and applications / / edited by Yoon Yeo |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, 2013 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) | YeoYoon |
| Soggetto topico |
Nanoparticles
Drug delivery systems Pharmaceutical biotechnology |
| ISBN |
1-299-24223-5
1-118-57054-5 |
| Classificazione | SCI013060 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Nanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications; Contents; Preface; Contributors; 1 Tumor-Targeted Nanoparticles: State-of-the-Art and Remaining Challenges; 1.1 INTRODUCTION; 1.2 FUNCTIONS OF NANOPARTICLES; 1.3 TUMOR-TARGETED NANOPARTICLES; 1.3.1 Passive Targeting; 1.3.2 Active Targeting; 1.3.3 Target-Activated Systems; 1.4 REMAINING CHALLENGES IN THE DEVELOPMENT OF TUMOR-TARGETED NANOPARTICLES; 1.4.1 NP Stability; 1.4.2 Heterogeneous Tumor Vasculature; 1.4.3 NP Distribution in Tumors; 1.4.4 Regulatory Considerations; 1.5 FUTURE PERSPECTIVES
1.5.1 In Vitro Models1.5.2 In Vivo Models; 1.5.3 New Targets; 1.5.4 New Therapeutic Agents; Acknowledgments; REFERENCES; 2 Applications of Ligand-Engineered Nanomedicines; 2.1 INTRODUCTION; 2.1.1 Nanoparticulate Drug Delivery; 2.1.2 Engineered Nanoparticulate Drug Delivery; 2.2 LIGAND-MEDIATED DELIVERY; 2.2.1 Antibodies; 2.2.2 Peptides and Proteins; 2.2.3 Sugars and Polysaccharides; 2.2.4 Small Molecule Chemicals; 2.3 CURRENT CHALLENGES IN CLINICAL DEVELOPMENT OF LIGAND-MODIFIED NANOMEDICINE; 2.3.1 Nonclinical and Clinical Studies; 2.3.2 Challenges and Future Perspectives; 2.4 CONCLUSIONS AcknowledgmentsREFERENCES; 3 Lipid Nanoparticles for the Delivery of Nucleic Acids; 3.1 INTRODUCTION; 3.2 BARRIERS TO SYSTEMIC GENE DELIVERY; 3.2.1 Extracellular Barriers; 3.2.2 Intracellular Barriers; 3.3 COMPONENTS OF LNPs; 3.3.1 Cationic Lipid; 3.3.2 Neutral Lipid; 3.3.3 Anionic Lipid; 3.3.4 PEG-Lipid Conjugates; 3.4 FORMULATIONS OF THE LNP FOR NUCLEIC ACIDS ENCAPSULATION; 3.4.1 Self-Assembly; 3.4.2 Detergent Dialysis; 3.4.3 Nanometric Calcium Phosphate/siRNA Precipitation; 3.5 ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS WITH LNPs; 3.5.1 Brain-Targeted Delivery; 3.5.2 Liver-Targeted Delivery 3.5.3 Lung-Targeted Delivery3.5.4 Kidney-Targeted Delivery; 3.6 CURRENT CHALLENGES TO THE DEVELOPMENT OF LNPs; 3.7 FUTURE PERSPECTIVES; Acknowledgments; REFERENCES; 4 Photosensitive Liposomes as Potential Targeted Therapeutic Agents; 4.1 INTRODUCTION; 4.2 EXPERIMENTAL PROCEDURES; 4.2.1 Materials; 4.2.2 Synthesis of 1-Bromo-3-hexadecylthiobenzene (1); 4.2.3 Synthesis of 9-[3-Hexadecylthiophenyl] anthracene (2); 4.2.4 Synthesis of 9-[3-Hexadecyl-3'-cyanobenzylsulfonium] phenylanthracene Trifluoromethanesulfonate (C16-An-PAG) (3); 4.2.5 Liposome Preparation; 4.2.6 Dynamic Light Scattering 4.2.7 Photoexcitation Method4.2.8 Calcium Ion Release Assay; 4.2.9 Negative Stain Transmission Electron Microscopy; 4.2.10 Animal Studies; 4.3 RESULTS AND DISCUSSION; 4.3.1 DOPE:LysoPlsC Liposomes Using C16-An-PAG as a Photosensitizer; 4.3.2 PPlsC Liposomes Using Bchl a as a Photosensitizer; 4.3.3 Folate Receptor (FR)-Targeted DPPlsC Liposomes Using AlPcS4-4 as a Photosensitizer; 4.4 CONCLUSIONS; 4.5 PROSPECTS FOR LIGHT-ACTIVATED LIPOSOMAL DRUG DELIVERY; Acknowledgments; REFERENCES; 5 Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery 5.1 RECENT ADVANCES IN DENDRITIC NANOMATERIALS |
| Record Nr. | UNINA-9911136253403321 |
| Hoboken, N.J., : Wiley, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||